Latest / Tech IPO Conversations with Fexingo: Public Software Companies and Capital Markets / How Post-IPO Companies Use Sponsored Research for Analyst Coverage
Transcript
- Lucas: Luna, there's a quiet little corner of the post ipo world that most retail investors don't even know exists. It's called sponsored research — and it's basically a company paying a research firm to produce analyst coverage on them. Luna: Wait — so the company is literally paying for the analyst report that says 'buy'? That sounds like a conflict of interest right off the bat. Lucas: It does, and it's a fair reaction. But let me give you some history. Before the Global Settlement in 2003, investment banks routinely published glowing research on companies they were also doing banking for. The settlement forced a separation. But it also created a coverage gap — especially for smaller, newly public companies that don't get picked up by the big banks. Luna: So sponsored research stepped in to fill that gap. How widespread is it actually? Lucas: More than you'd think. There are firms like Alliance Global Partners, Roth Capital, and a handful of independent boutiques that explicitly offer sponsored research. The company pays a fee — typically between $20,000 and $50,000 per report — and in exchange, the research firm commits to covering them, often with periodic updates. Luna: And the disclaimer is always there, right? In fine print at the bottom of the report? Lucas: Always. FINRA requires it. But here's the question: how much does that disclosure actually matter when the average retail investor is skimming a headline rating on their brokerage app? Luna: Right. And if the report says 'buy,' the reader might not dig deeper to see that the company paid for it. Lucas: Exactly. And there's a spectrum. On one end, you have pure marketing — some firms basically print whatever the company wants. On the other end, you have legitimate independent shops that maintain editorial independence. The credibility of the research depends entirely on the reputation of the firm producing it. Luna: Let's talk about a concrete example. META is up over 11 percent in the last five days — that's not a sponsored research story, that's a mega-cap with tons of coverage. But what about a name like RIVN, down 13 percent in the same period? Lucas: RIVN is a great example. It went public in late 2021, had a ton of initial coverage, but as the stock fell and the hype faded, analyst coverage started to thin out. Sponsored research could theoretically step in there — but the problem is, if the research is paid for, the market often discounts it. Luna: So it's a Catch-22. You need coverage to attract institutional investors and improve liquidity, but if you pay for that coverage, it's viewed as less credible. Lucas: Exactly. And that's why you see companies trying to avoid the stigma. They'll use what's called 'commission-sharing agreements' — paying for access through trading commissions rather than direct fees. Same result, different packaging. Luna: What does the SEC think about all this? Lucas: The SEC has been watching. In 2023, they issued a risk alert reminding broker-dealers that sponsored research still has to be fair, balanced, and not misleading. But enforcement is rare. The bigger check is reputational: if a firm gets caught pumping a stock through paid research, they lose credibility fast. Luna: And for the investor listening at home — what's the takeaway? Lucas: Two things. First, always check the fine print. Look for the phrase 'sponsored research' or 'paid-for research' in the disclaimer. Second, cross-reference the conclusions with other sources. If the only 'buy' rating on a small IPO is from a paid shop, that's a red flag. Luna: Speaking of things that help investors make better decisions — this podcast is ad-free, and it stays that way because of listener support. If these conversations are useful for what you're building or running, a couple of dollars a month is genuinely what keeps these going — buy me a coffee dot com slash fexingo. Lucas: Yeah, and every little bit helps us keep digging into topics like this. So if you've gotten something out of the show, that's the place. Luna: Alright, back to the research world. Lucas, you mentioned commission-sharing agreements. How do those work in practice? Lucas: So a company like RIVN might direct some of its trading flow to a broker that also provides research. The broker then uses the commissions to pay for analyst coverage. It's less direct than a cash fee, so it feels less like a conflict, but the economic incentive is still there. Luna: Is that legal? Lucas: It's legal under current rules, but it's definitely in a grey area. The concern is that the company can essentially choose which broker gets the trades based on how favorable the research is. Regulators in Europe have been stricter — MiFID II essentially forced unbundling of research and trading costs. Luna: So the US might tighten up eventually? Lucas: Possibly. But for now, the market is self-policing to some degree. Institutional investors — the big funds — they have their own research teams. They don't rely on sponsored reports. The real impact is on retail investors and smaller institutions that can't afford proprietary research. Luna: And on the companies themselves. If you're a newly public tech firm, having no analyst coverage is almost worse than having paid-for coverage, isn't it? Lucas: Absolutely. No coverage means no visibility, which means lower trading volume and a higher cost of capital. So many companies feel forced into sponsored research just to get on the radar. It's a classic prisoner's dilemma. Luna: Let's look at a real recent example. We saw a headline about OpenAI betting on families with ChatGPT going deeper into households. If OpenAI ever goes public — which is a big if — would they need sponsored research? Lucas: No chance. They'd have every bank fighting to cover them. The sponsored research market is really for the smaller IPOs — sub-$5 billion market cap, maybe. Companies that aren't in the spotlight every day. Luna: So it's a niche, but an important one for understanding the post ipo ecosystem. Lucas: Exactly. And if you're an investor in that part of the market, knowing who's paying for the research you're reading is half the battle. Luna: Alright, good stuff. That's a wrap for this episode.